Physician profile
Eric Cheung
NPI 1013421973
$9,313.95
in general payments reported to CMS, 2019-2025
35 companies · $2,247 in 2025
The $2,247 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,209 · 2022: $1,409 · 2023: $2,318 · 2024: $2,131 · 2025: $2,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,696.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,445.88 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $1,232.88 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $851.92 | 2021-2025 | |
| Gilead Sciences, INC. | $617.30 | 2023-2025 | Epclusa, Vemlidy |
| Abbvie INC. | $579.22 | 2021-2025 | |
| Novo Nordisk INC | $501.17 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Ibsa Pharma INC. | $464.96 | 2023-2025 | Licart, Tirosint, Tirosint |
| Redhill Biopharma INC. | $415.45 | 2021-2024 | Talicia, Talicia |
| Astrazeneca Pharmaceuticals LP | $382.01 | 2021-2025 | Breztri, Farxiga |
| Phathom Pharmaceuticals, INC. | $375.54 | 2025 | Voquezna |
| Lilly USA, LLC | $343.36 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $306.97 | 2021-2025 | Livalo, Seglentis, Zoryve |
| Aimmune Therapeutics, INC. | $216.62 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $181.78 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.07 | 2021-2025 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $145.35 | 2022-2025 | Steglatro, Januvia, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.82 | 2021-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $133.95 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Dexcom, INC. | $111.11 | 2022-2023 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $106.69 | 2024-2025 | Ibsrela |
| Amarin Pharma, INC. | $86.09 | 2021 | |
| Hikma Pharmaceuticals USA | $62.71 | 2021-2023 | Ryaltris, Mitigare |
| Kite Pharma, INC. | $61.50 | 2024-2025 | Yescarta |
| Bioventus LLC | $52.40 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.19 | 2022 | |
| Xeris Pharmaceuticals, INC. | $35.41 | 2021 | |
| Radius Health, INC. | $32.30 | 2021 | |
| Alkermes, INC. | $23.31 | 2021 | |
| Nestle Healthcare Nutrition INC. | $21.22 | 2022 | |
| Qiagen, LLC | $19.65 | 2024 | |
| Pfizer INC. | $17.21 | 2023 | |
| Eyevance Pharmaceuticals LLC | $16.78 | 2021 | |
| Cranial Technologies, INC | $15.13 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.